Миофасциальная боль является актуальной междисциплинарной медицинской проблемой. Она выявляется более чем у половины пациентов молодого и среднего возраста, точных данных о ее распространенности среди пожилых людей нет. В настоящее время отсутствует систематизированный подход к терминологии и нозологической принадлежности миофасциальной боли. Авторами приводятся и оцениваются значимые факторы возникновения миофасциальной боли и диагностические критерии миофасциального болевого синдрома. В алгоритме лечения делается акцент на общих принципах терапии, механизмах действия и показаниях для обоснованного применения наружных форм НПВП, в частности препарата Вольтарен Эмульгель 12 часов, в качестве как самостоятельного метода лечения при слабой и умеренной боли, так и дополнения к основной терапии, направленной на подавление боли.
One of the main reasons for seeking medical help is myofascial syndrome (MFS), which is manifested by local inflammation with elements of degenerative changes in the affected tissue, pain and muscle spasm due to dysfunctional disorders in the nociceptive system and a decrease in the quality of life. This review discusses etiopathogenesis in detail, taking into account the factors predisposing to the development of MFS, which are divided into anatomical, ergonomic, medical and psychosocial, and also provides diagnostic criteria for pain MFS, including 5 large and 3 small criteria necessary for diagnosis. The second part of the review examines the indications, efficacy, safety, and benefits of topical forms of nonsteroidal anti-inflammatory drugs (NSAIDs), which have a moderate effect on pain, but have a much better safety profile due to reduced systemic absorption. The use of topical drugs allows you to create an effective concentration of the drug directly in the lesion and avoid undesirable systemic effects. Experts strongly recommend prescribing primarily topical, rather than oral, NSAIDs to patients aged 65 years and older who have concomitant cardiovascular and renal pathology, as well as diseases of the gastrointestinal tract. In more detail, the review examines topical forms of diclofenac, which differ in the maximum degree of transdermal penetration compared to other NSAIDs and the effect of slow release of the active substance into the surrounding tissues.
The aim of this study was to compare the haemodynamic effects ofacebutolol, a ~I-selective adrenoceptor blocker with intrinsic sympathomimetic activity, and propranolol, a nonselective ~-adrenoceptor blocker without intrinsic sympathomimetic activity. 44 males aged 35 to 59 (mean 49.7 ± 1.0) years with mild to moderate arterial hypertension (diastolic blood pressure 95 to 114mm Hg) without severe concomitant diseases requiring medication, and without contraindications to ~-adrenoceptor blockade, were included in this double-blind randomised parallel group study. It was shown that during 12 weeks' treatment the magnitude and duration of the antihypertensive effect of acebutolol 400 or 800mg daily did not differ from that of propranolol 80 or l60mg daily. However. there was a trend towards more patients achieving a full or partial antihypertensive effect with acebutolol than propranoloL Moreover, bradycardia was more pronounced with propranoloL The antihypertensive effect of acebutolol was observed after 2 weeks and maintained throughout all 12 weeks of treatment. Unlike propranolol, acebutolol did not cause such unwanted haemodynamic effects as decreased cardiac output and increased total peripheral resistance. Acebutolol was well tolerated. NSNS NS NS NS NS NS NS NS NS NS NS NS NS NS NS
Back pain (dorsopathy) is one of the common syndromes, which is specific to the whole group of diseases with similar clinical presentations. Ankylosing spondylarthritis (Bechterew’s disease) with a distinct clinical course evolving not only spinal and sacroiliac lesion, but also visceral changes is discussed using the example of a clinical case. The authors discuss Nimesulide, a drug from NSAID (non-steroidal anti-inflammatory drugs) group, in the treatment of inflammatory presentations of the disease and evaluate its efficacy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.